Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A carries a market capitalization of 19.05B, placing it among publicly traded companies globally. Its enterprise value stands at 15.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A has 1.02B shares outstanding.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 17.39. The price-to-sales ratio is 3.08, and the price-to-book ratio stands at 2.27.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 12.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.35B versus a market cap of 19.05B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A maintains a current ratio of 6.22, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.86, indicating moderate leverage, while an interest coverage ratio of 602.61 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 13.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.48 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.62, useful for judging operating efficiency across full business cycles. The company generates approximately 1.03M in revenue per employee across its workforce of 5,983.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.34 indicates how many times Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A recorded 147.32M in income tax expense. That works out to an effective tax rate of 11.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.24B, leaving 1.09B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A's stock has declined approximately 16.72% over the past 52 weeks. The 50-day moving average sits at 21.96, while the 200-day moving average is 21.97.

Over the twelve months ended June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A generated 6.16B in revenue and converted that into 1.09B in net income, yielding earnings per share of 1.08. EBITDA reached 1.26B, while operating income came in at 1.25B.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A holds 3.74B in cash and equivalents against 72.04M in total debt, resulting in a net debt position of -1.18B. Total book value stands at 8.39B, with working capital of 5.65B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A posted a gross margin of 71.10, reflecting its pricing power and cost economics. The operating margin of 20.25 and net profit margin of 17.73 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A paid dividends of 0.36 per share. The dividend payout ratio of 33.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A shareholders.

Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 12, 2017 with a 5:8 split ratio.

As of June 30, 2026, Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 12.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.